Maropitant inhibits CYP enzymes that metabolize some opioids, potentially increasing opioid plasma levels. Also synergistic antiemetic effect (desired).
Management: Antiemetic co-administration is standard practice. Monitor for increased sedation. Clinical significance of PK interaction is modest.
Synergistic sedation and analgesia. Dexmedetomidine reduces opioid MAC-sparing by additional 40-60%. Additive bradycardia.
Management: Intended combination — reduce opioid dose by 30-50%. Monitor heart rate. Profound bradycardia may require glycopyrrolate.
Opioids slow GI motility (anti-prokinetic). Metoclopramide stimulates GI motility (prokinetic). Pharmacologically opposing effects.
Management: Metoclopramide antiemetic effect (D2 blockade) is preserved, but prokinetic effect is reduced by concurrent opioids. For prokinetic benefit, may need higher metoclopramide dose.
Additive CNS and respiratory depression via different mechanisms (mu-opioid vs GABA-A).
Management: Monitor respiratory rate and SpO2. Reduce opioid dose when adding benzodiazepine.
Synergistic sedation and analgesia. Additive bradycardia. Standard premedication combination at reduced doses.
Management: Intended combination. Reduce individual doses by 30-50%. Monitor heart rate. Reverse medetomidine with atipamezole when appropriate.